Last Update: Jun 03, 2024
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
ClinicalTrials.gov Identifier:
NCT05073120
Novartis Reference Number:CBYL719C2005
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This is a multinational, non-interventional, cross-sectional survey conducted among HCPs
based in the EU/EEA who prescribe Piqray. The survey will assess the knowledge of HCPs
prescribing Piqray in relation to the management of hyperglycemia in patients treated
with Piqray. The survey will endeavor to collect a minimum to 30-50 completed surveys.

Breast Cancer
Recruiting
100
Feb 28, 2022
Dec 30, 2024
All
18 Years - (Adult, Older Adult)

Interventions

Other

Piqray Prescriber's/HCP guide for hyperglycemia

oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.

Eligibility Criteria

Inclusion Criteria:

- Has prescribed Piqray to at least 1 locally advanced or MBC patient within 6 months
prior to completing the survey.

- Provides permission to share their anonymized responses in aggregate with EMA or
NCAs, if requested.

Exclusion Criteria:

HCPs who are direct employees of Novartis, the EMA (or any other regulatory bodies), or
ICON.

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111